Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Michael Lincoff

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Devices

Stents

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
125
Topol, Eric
61
Califf, Robert
47
Harrington, Robert
37
Kleiman, Neal
33
Tcheng, James
29
Ellis, Stephen
28
Ohman, Magnus
22
Bhatt, Deepak
21
Kereiakes, Dean
21
Wolski, Kathy
21
Simoons, Maarten
20
Moliterno, David
18
White, Harvey
18
Stone, Gregg
16
Mehran, Roxana

Sign-in to see all Coauthors

Publications

TOP 3
Krishnaswamy Amar; Lincoff A Michael; Menon Venu
Magnitude and consequences of missing the acute infarct-related circumflex artery.
Doll Jacob A; Nikolsky Eugenia; Stone Gregg W; Mehran Roxana; Lincoff A Michael; Caixeta Adriano; McLaurin Brent; Cristea Ecaterina; Fahy Martin; Kesanakurthy Vijaya; Lansky Alexandra J
Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
Nikolsky Eugenia; Stone Gregg W; Kirtane Ajay J; Dangas George D; Lansky Alexandra J; McLaurin Brent; Lincoff A Michael; Feit Frederick; Moses Jeffrey W; Fahy Martin; Manoukian Steven V; White Harvey D; Ohman E Magnus; Bertrand Michel E; Cox David A; Mehran Roxana
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Michael Lincoff (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Krishnaswamy Amar; Lincoff A Michael; Menon Venu
Magnitude and consequences of missing the acute infarct-related circumflex artery.
American heart journal 2009;158(5):706-12.
2009: Doll Jacob A; Nikolsky Eugenia; Stone Gregg W; Mehran Roxana; Lincoff A Michael; Caixeta Adriano; McLaurin Brent; Cristea Ecaterina; Fahy Martin; Kesanakurthy Vijaya; Lansky Alexandra J
Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
Journal of interventional cardiology 2009;22(5):453-9.
2009: Nikolsky Eugenia; Stone Gregg W; Kirtane Ajay J; Dangas George D; Lansky Alexandra J; McLaurin Brent; Lincoff A Michael; Feit Frederick; Moses Jeffrey W; Fahy Martin; Manoukian Steven V; White Harvey D; Ohman E Magnus; Bertrand Michel E; Cox David A; Mehran Roxana
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Journal of the American College of Cardiology 2009;54(14):1293-302.
2009: Askari Arman T; Shishehbor Mehdi H; Kaminski Matthew A; Riley Michael J; Hsu Amy; Lincoff A Michael;
The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from Global Use of Strategies to Open coronary arteries (GUSTO) V.
American heart journal 2009;158(2):238-43.
2009: Prasad Abhiram; Gersh Bernard J; Bertrand Michel E; Lincoff A Michael; Moses Jeffrey W; Ohman E Magnus; White Harvey D; Pocock Stuart J; McLaurin Brent T; Cox David A; Lansky Alexandra J; Mehran Roxana; Stone Gregg W
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Journal of the American College of Cardiology 2009;54(5):477-86.
2009: Chhatriwalla Adnan K; Cam Akin; Unzek Samuel; Bhatt Deepak L; Raymond Russell E; Lincoff A Michael; Whitlow Patrick L; Ellis Stephen G; Tuzcu E Murat; Kapadia Samir R
Drug-eluting stent fracture and acute coronary syndrome.
Cardiovascular revascularization medicine : including molecular interventions 2009;10(3):166-71.
2009: Henry Robert R; Lincoff A Michael; Mudaliar Sunder; Rabbia Michael; Chognot Cathy; Herz Matthias
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Lancet 2009;374(9684):126-35.
2009: Ebrahimi Ramin; Dyke Cornelius; Mehran Roxana; Manoukian Steven V; Feit Frederick; Cox David A; Gersh Bernard J; Ohman E Magnus; White Harvey D; Moses Jeffrey W; Ware James H; Lincoff A Michael; Stone Gregg W
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Journal of the American College of Cardiology 2009;53(21):1965-72.
2009: Shishehbor Mehdi H; Filby Steven J; Chhatriwalla Adnan K; Christofferson Ryan D; Jain Anil; Kapadia Samir R; Lincoff A Michael; Bhatt Deepak L; Ellis Stephen G
Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia.
JACC. Cardiovascular interventions 2009;2(4):329-36.
2009: Becker Matthew C; Wang Thomas H; Wisniewski Lisa; Wolski Kathy; Libby Peter; Lüscher Thomas F; Borer Jeffrey S; Mascette Alice M; Husni M Elaine; Solomon Daniel H; Graham David Y; Yeomans Neville D; Krum Henry; Ruschitzka Frank; Lincoff A Michael; Nissen Steven E;
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
American heart journal 2009;157(4):606-12.
2009: Aoki Jiro; Lansky Alexandra J; Mehran Roxana; Moses Jeffery; Bertrand Michel E; McLaurin Brent T; Cox David A; Lincoff A Michael; Ohman E Magnus; White Harvey D; Parise Helen; Leon Martin B; Stone Gregg W
Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial.
Circulation 2009;119(5):687-98.
2008: Lincoff A Michael; Steinhubl Steven R; Manoukian Steven V; Chew Derek; Pollack Charles V; Feit Frederick; Ware James H; Bertrand Michel E; Ohman E Magnus; Desmet Walter; Cox David A; Mehran Roxana; Stone Gregg W;
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
JACC. Cardiovascular interventions 2008;1(6):639-48.
2008: Pinto Duane S; Stone Gregg W; Shi Chunxue; Dunn Elizabeth S; Reynolds Matthew R; York Meghan; Walczak Joshua; Berezin Ronna H; Mehran Roxana; McLaurin Brent T; Cox David A; Ohman E Magnus; Lincoff A Michael; Cohen David J;
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
Journal of the American College of Cardiology 2008;52(22):1758-68.
2008: Aronow Herbert D; Lincoff A Michael; Quinn Martin J; McRae A Thomas; Gurm Hitinder S; Houghtaling Penny L; Granger Christopher B; Harrington Robert A; Van de Werf Franz; Topol Eric J; Lauer Michael S;
Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction.
The American journal of cardiology 2008;102(9):1119-24.
2008: White Harvey D; Ohman E Magnus; Lincoff A Michael; Bertrand Michel E; Colombo Antonio; McLaurin Brent T; Cox David A; Pocock Stuart J; Ware James A; Manoukian Steven V; Lansky Alexandra J; Mehran Roxana; Moses Jeffrey W; Stone Gregg W
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Journal of the American College of Cardiology 2008;52(10):807-14.
2008: Harrington Robert A; Becker Richard C; Cannon Christopher P; Gutterman David; Lincoff A Michael; Popma Jeffrey J; Steg Gabriel; Guyatt Gordon H; Goodman Shaun G;
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest 2008;133(6 Suppl):670S-707S.
2008: Warkentin Theodore E; Greinacher Andreas; Koster Andreas; Lincoff A Michael;
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest 2008;133(6 Suppl):340S-380S.
2008: Hiatt William R; Lincoff A Michael; Harrington Robert A
Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration.
Circulation 2008;117(22):2956-7.
2008: White Harvey D; Chew Derek P; Hoekstra James W; Miller Chadwick D; Pollack Charles V; Feit Frederick; Lincoff A Michael; Bertrand Michel; Pocock Stuart; Ware James; Ohman E Magnus; Mehran Roxana; Stone Gregg W
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Journal of the American College of Cardiology 2008;51(18):1734-41.
2008: Nissen Steven E; Nicholls Stephen J; Wolski Kathy; Rodés-Cabau Josep; Cannon Christopher P; Deanfield John E; Després Jean-Pierre; Kastelein John J P; Steinhubl Steven R; Kapadia Samir; Yasin Muhammad; Ruzyllo Witold; Gaudin Christophe; Job Bernard; Hu Bo; Bhatt Deepak L; Lincoff A Michael; Tuzcu E Murat;
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
JAMA : the journal of the American Medical Association 2008;299(13):1547-60.
2008: Nissen Steven E; Nicholls Stephen J; Wolski Kathy; Nesto Richard; Kupfer Stuart; Perez Alfonso; Jure Horacio; De Larochellière Robert; Staniloae Cezar S; Mavromatis Kreton; Saw Jacqueline; Hu Bo; Lincoff A Michael; Tuzcu E Murat;
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
JAMA : the journal of the American Medical Association 2008;299(13):1561-73.
2008: Madhwal Surabhi; Lincoff A Michael; Rolston David D K
Should patients on long-term warfarin take aspirin for heart disease?
Cleveland Clinic journal of medicine 2008;75(3):206-8.
2008: Novaro Gian M; Asher Craig R; Bhatt Deepak L; Moliterno David J; Harrington Robert A; Lincoff A Michael; Newby L Kristin; Tcheng James E; Hsu Amy P; Pinski Sergio L
Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites.
The American journal of cardiology 2008;101(4):506-9.
2008: Ashley Kellan E; Lincoff A Michael
Pharmacologic inhibition of platelet function: correlation between in vitro tests of platelet function and clinical outcomes.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2008;8(5):283-95.
2007: Stone Gregg W; Ware James H; Bertrand Michel E; Lincoff A Michael; Moses Jeffrey W; Ohman E Magnus; White Harvey D; Feit Frederick; Colombo Antonio; McLaurin Brent T; Cox David A; Manoukian Steven V; Fahy Martin; Clayton Tim C; Mehran Roxana; Pocock Stuart J;
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
JAMA : the journal of the American Medical Association 2007;298(21):2497-506.
2007: Feit Frederick; Voeltz Michele D; Attubato Michael J; Lincoff A Michael; Chew Derek P; Bittl John A; Topol Eric J; Manoukian Steven V
Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial.
The American journal of cardiology 2007;100(9):1364-9.
2007: Reynolds Harmony R; Farkouh Michael E; Lincoff A Michael; Hsu Amy; Swahn Eva; Sadowski Zygmunt P; White Jennifer A; Topol Eric J; Hochman Judith S;
Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V.
Archives of internal medicine 2007;167(19):2054-60.
2007: Lincoff A Michael; Wolski Kathy; Nicholls Stephen J; Nissen Steven E
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
JAMA : the journal of the American Medical Association 2007;298(10):1180-8.
2007: Dyke Cornelius M; Aldea Gabriel; Koster Andreas; Smedira Nicholas; Avery Edwin; Aronson Solomon; Spiess Bruce D; Lincoff A Michael
Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies.
The Annals of thoracic surgery 2007;84(3):836-9.
2007: Anderson Jeffrey L; Adams Cynthia D; Antman Elliott M; Bridges Charles R; Califf Robert M; Casey Donald E; Chavey William E; Fesmire Francis M; Hochman Judith S; Levin Thomas N; Lincoff A Michael; Peterson Eric D; Theroux Pierre; Wenger Nanette Kass; Wright R Scott; Smith Sidney C; Jacobs Alice K; Adams Cynthia D; Anderson Jeffrey L; Antman Elliott M; Halperin Jonathan L; Hunt Sharon A; Krumholz Harlan M; Kushner Frederick G; Lytle Bruce W; Nishimura Rick; Ornato Joseph P; Page Richard L; Riegel Barbara;
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
Journal of the American College of Cardiology 2007;50(7):e1-e157.
2007: Anderson Jeffrey L; Adams Cynthia D; Antman Elliott M; Bridges Charles R; Califf Robert M; Casey Donald E; Chavey William E; Fesmire Francis M; Hochman Judith S; Levin Thomas N; Lincoff A Michael; Peterson Eric D; Theroux Pierre; Wenger Nanette Kass; Wright R Scott; Smith Sidney C; Jacobs Alice K; Halperin Jonathan L; Hunt Sharon A; Krumholz Harlan M; Kushner Frederick G; Lytle Bruce W; Nishimura Rick; Ornato Joseph P; Page Richard L; Riegel Barbara;
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
Circulation 2007;116(7):e148-304.
2007: Nikolsky Eugenia; Mehran Roxana; Dangas George; Fahy Martin; Na Yingbo; Pocock Stuart J; Lincoff A Michael; Stone Gregg W
Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.
European heart journal 2007;28(16):1936-45.
2007: Galla John M; Lincoff A Michael
The role of clopidogrel in the management of ischemic heart disease.
Current opinion in cardiology 2007;22(4):273-9.
2007: Gibson C Michael; Ten Yuli; Murphy Sabina A; Ciaglo Lauren N; Southard Matthew C; Lincoff A Michael; Waksman Ron
Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis).
The American journal of cardiology 2007;99(12):1687-90.
2007: Voeltz Michele D; Patel Amar D; Feit Frederick; Fazel Reza; Lincoff A Michael; Manoukian Steven V
Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention.
The American journal of cardiology 2007;99(11):1513-7.
2007: Gurm Hitinder S; Rajagopal Vivek; Bhatt Deepak L; Ellis Stephen G; Lincoff A Michael
The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy.
The Journal of invasive cardiology 2007;19(5):225-8.
2007: Manoukian Steven V; Feit Frederick; Mehran Roxana; Voeltz Michele D; Ebrahimi Ramin; Hamon Martial; Dangas George D; Lincoff A Michael; White Harvey D; Moses Jeffrey W; King Spencer B; Ohman E Magnus; Stone Gregg W
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.
Journal of the American College of Cardiology 2007;49(12):1362-8.
2007: Stone Gregg W; White Harvey D; Ohman E Magnus; Bertrand Michel E; Lincoff A Michael; McLaurin Brent T; Cox David A; Pocock Stuart J; Ware James H; Feit Frederick; Colombo Antonio; Manoukian Steven V; Lansky Alexandra J; Mehran Roxana; Moses Jeffrey W;
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Lancet 2007;369(9565):907-19.
2007: Stone Gregg W; Bertrand Michel E; Moses Jeffrey W; Ohman E Magnus; Lincoff A Michael; Ware James H; Pocock Stuart J; McLaurin Brent T; Cox David A; Jafar M Zubair; Chandna Harish; Hartmann Franz; Leisch Franz; Strasser Ruth H; Desaga Martin; Stuckey Thomas D; Zelman Richard B; Lieber Ira H; Cohen David J; Mehran Roxana; White Harvey D;
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
JAMA : the journal of the American Medical Association 2007;297(6):591-602.
2007: Koster Andreas; Dyke Cornelius M; Aldea Gabriel; Smedira Nicholas G; McCarthy Harry L; Aronson Solomon; Hetzer Roland; Avery Edwin; Spiess Bruce; Lincoff A Michael
Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.
The Annals of thoracic surgery 2007;83(2):572-7.
2007: Hodgson John McB; Stone Gregg W; Lincoff A Michael; Klein Lloyd; Walpole Howard; Bottner Randy; Weiner Bonnie H; Leon Martin B; Feldman Ted; Babb Joseph; Dehmer Gregory J;
Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2007;69(3):327-33.
2006: Stone Gregg W; McLaurin Brent T; Cox David A; Bertrand Michel E; Lincoff A Michael; Moses Jeffrey W; White Harvey D; Pocock Stuart J; Ware James H; Feit Frederick; Colombo Antonio; Aylward Philip E; Cequier Angel R; Darius Harald; Desmet Walter; Ebrahimi Ramin; Hamon Martial; Rasmussen Lars H; Rupprecht Hans-Jürgen; Hoekstra James; Mehran Roxana; Ohman E Magnus;
Bivalirudin for patients with acute coronary syndromes.
The New England journal of medicine 2006;355(21):2203-16.
2006: Saw Jacqueline; Bhatt Deepak L; Moliterno David J; Brener Sorin J; Steinhubl Steven R; Lincoff A Michael; Tcheng James E; Harrington Robert A; Simoons Maarten; Hu TingFei; Sheikh Mobeen A; Kereiakes Dean J; Topol Eric J
The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.
Journal of the American College of Cardiology 2006;48(8):1567-72.
2006: Karha Juhana; Gurm Hitinder S; Rajagopal Vivek; Fathi Robert; Bavry Anthony A; Brener Sorin J; Lincoff A Michael; Ellis Stephen G; Bhatt Deepak L
Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
The American journal of cardiology 2006;98(7):906-10.
2006: Maroo Anjli; Rasmussen Peter A; Masaryk Thomas J; Ellis Stephen G; Lincoff A Michael; Kapadia Samir
Stent-assisted detachable coil embolization of pseudoaneurysms in the coronary circulation.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2006;68(3):409-15.
2006: Kao John; Lincoff A Michael; Topol Eric J; Madrid Antonio; J Price Matthew; Sawhney Neil; Teirstein Paul S
Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2006;68(3):352-6.
2006: Exaire J Emilio; Butman Samuel M; Ebrahimi Ramin; Kleiman Neal S; Harrington Robert A; Schweiger Marc J; Bittl John A; Wolski Kathy; Topol Eric J; Lincoff A Michael;
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
American heart journal 2006;152(1):157-63.
2006: Rajagopal Vivek; Lincoff A Michael; Cohen David J; Gurm Hitinder S; Hu Tingfei; Desmet Walter J; Kleiman Neal S; Bittl John A; Feit Frederick; Topol Eric J
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
American heart journal 2006;152(1):149-54.
2006: Patel Taral N; Kreindel Mark; Lincoff A Michael
Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
The Journal of invasive cardiology 2006;18(7):E211-3.
2006: Robertson Jason O; Lincoff A Michael; Wolski Kathy; Topol Eric J
Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention.
The American journal of cardiology 2006;97(12):1679-84.
2006: Lincoff A Michael
How do unfractionated and low-molecular-weight heparin compare after ST-segment elevation MI?
Nature clinical practice. Cardiovascular medicine 2006;3(6):300-1.
2006: Blankenship James C; Haldis Tom; Feit Frederick; Hu Tingfei; Kleiman Neal S; Topol Eric J; Lincoff A Michael;
Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy).
The American journal of cardiology 2006;97(11):1591-6.
2006: Chacko Matthews; Lincoff A Michael; Wolski Katherine E; Cohen David J; Bittl John A; Lansky Alexandra J; Tsuchiya Yoshihiro; Betriu Amadeo; Yen Michael H; Chew Derek P; Cho Leslie; Topol Eric J
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
American heart journal 2006;151(5):1032.e1-7.
2006: Kaul Padma; Chang Wei-Ching; Lincoff A Michael; Aylward Philip; Betriu Amadeo; Bode Christoph; Califf Robert M; Ohman E Magnus; Guetta Victor; Steg P Gabriel; Van de Werf Frans; Armstrong Paul W
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial.
European heart journal 2006;27(10):1198-206.
2006: Bavry Anthony A; Lincoff A Michael
Is clopidogrel cardiovascular medicine's double-edged sword?
Circulation 2006;113(13):1638-40.
2006: Wang Kai; Zhou Zhongmin; Zhang Ming; Fan Liming; Forudi Farhad; Zhou Xiaorong; Qu Wu; Lincoff A Michael; Schmidt Ann Marie; Topol Eric J; Penn Marc S
Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
The Journal of pharmacology and experimental therapeutics 2006;317(1):37-43.
2006: Smedira Nicholas G; Dyke Cornelius M; Koster Andreas; Jurmann Michael; Bhatia Devinder S; Hu Tingfei; McCarthy Harry L; Lincoff A Michael; Spiess Bruce D; Aronson Solomon
Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study.
The Journal of thoracic and cardiovascular surgery 2006;131(3):686-92.
2006: Dyke Cornelius M; Smedira Nicholas G; Koster Andreas; Aronson Solomon; McCarthy Harry L; Kirshner Ronald; Lincoff A Michael; Spiess Bruce D
A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.
The Journal of thoracic and cardiovascular surgery 2006;131(3):533-9.
2006: Rao Sunil V; O'Grady Kristi; Pieper Karen S; Granger Christopher B; Newby L Kristin; Mahaffey Kenneth W; Moliterno David J; Lincoff A Michael; Armstrong Paul W; Van de Werf Frans; Califf Robert M; Harrington Robert A
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.
Journal of the American College of Cardiology 2006;47(4):809-16.
2005: Ebrahimi Ramin; Lincoff A Michael; Bittl John A; Chew Derek; Wolski Kathy; Wadhan Nitin; Toggart Edward J; Topol Eric J
Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis.
Journal of cardiovascular pharmacology and therapeutics 2005;10(4):209-16.
2005: Levine Glenn N; Lincoff A Michael; Ferguson James J; Mahaffey Kenneth W; Goodman Shaun G; Cannon Christopher P; Theroux Pierre; Fox Keith A A
Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2005;66(2):149-57.
2005: Wang Kai; Zhou Xiaorong; Zhou Zhongmin; Mal Niladri; Fan Liming; Zhang Ming; Lincoff A Michael; Plow Edward F; Topol Eric J; Penn Marc S
Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(8):1584-9.
2005: Nallamothu Brahmajee K; Bates Eric R; Hochman Judith S; Granger Christopher B; Guetta Victor; Wilcox Robert G; White Harvey D; Armstrong Paul W; Savonitto Stefano; Jia Gang; Lincoff A Michael; Topol Eric J;
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.
European heart journal 2005;26(15):1506-12.
2005: Brener Sorin J; Lincoff A Michael; Bates Eric R; Jia Gang; Armstrong Paul W; Guetta Victor; Hochman Judith S; Savonitto Stefano; Wilcox Robert G; White Harvey D; Topol Eric J;
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial.
American heart journal 2005;150(1):89-93.
2005: Chen Michael S; Lincoff A Michael
Direct thrombin inhibitors.
Current cardiology reports 2005;7(4):255-9.
2005: Gurm Hitinder S; Sarembock Ian J; Kereiakes Dean J; Young John J; Harrington Robert A; Kleiman Neal; Feit Frederick; Wolski Kathy; Bittl John A; Wilcox Robert; Topol Eric J; Lincoff A Michael
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
Journal of the American College of Cardiology 2005;45(12):1932-8.
2005: Mahaffey Kenneth W; Roe Matthew T; Kilaru Rakhi; French John K; Alexander John H; Berdan Lisa G; Van De Werf Frans; Simoons Maarten L; Weaver W Douglas; White Harvey D; Lincoff A Michael; Kleiman Neal S; Topol Eric J; Harrington Robert A
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.
The American journal of cardiology 2005;95(12):1404-8.
2005: Koster Andreas; Yeter Ruhi; Buz Semih; Kuppe Hermann; Hetzer Roland; Lincoff A Michael; Dyke Cornelius M; Smedira Nicholas G; Spiess Bruce
Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study.
The Journal of thoracic and cardiovascular surgery 2005;129(6):1391-4.
2005: Gurm Hitinder S; Rajagopal Vivek; Fathi Robert; Vivekanathan Deepak; Yadav Jay S; Bhatt Deepak L; Ellis Stephen G; Lincoff A Michael; Topol Eric J
Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center.
The American journal of cardiology 2005;95(6):716-21.
2005: Alexander J H; Yang H; Becker R C; Kodama K; Goodman S; Dyke C K; Kleiman N S; Hochman J S; Berger P B; Cohen E A; Lincoff A M; Burton J R; Bovill E G; Kawai C; Armstrong P W; Harrington R A;
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
Journal of thrombosis and haemostasis : JTH 2005;3(3):439-47.
2005: Rebeiz Abdallah G; Johanson Per; Green Cindy L; Crater Suzanne W; Roe Matthew T; Langer Anatoly; Giugliano Robert P; Lincoff A Michael; Newby L Kristin; Harrington Robert A; Topol Eric J; Califf Robert M; Wagner Galen S; Krucoff Mitchell W
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
The American journal of cardiology 2005;95(5):611-4.
2005: Chew Derek P; Lincoff A Michael; Gurm Hitinder; Wolski Katherine; Cohen David J; Henry Tim; Feit Frederick; Topol Eric J;
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
The American journal of cardiology 2005;95(5):581-5.
2005: Labinaz Marino; Mathias Jasmine; Pieper Karen; Granger Christopher B; Lincoff A Michael; Moliterno David J; Van de Werf Frans; Simes John; White Harvey D; Simoons Maarten L; Califf Robert M; Topol Eric J; Armstrong Paul W; Harrington Robert A
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.
European heart journal 2005;26(2):128-36.
2005: Wang Kai; Tarakji Khaldoun; Zhou Zhongmin; Zhang Ming; Forudi Farhad; Zhou Xiaorong; Koki Alane T; Smith Mark E; Keller Bradley T; Topol Eric J; Lincoff A Michael; Penn Marc S
Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.
Journal of cardiovascular pharmacology 2005;45(1):61-7.
2004: Chiu John H; Bhatt Deepak L; Ziada Khaled M; Chew Derek P; Whitlow Patrick L; Lincoff A Michael; Ellis Stephen G; Topol Eric J
Impact of female sex on outcome after percutaneous coronary intervention.
American heart journal 2004;148(6):998-1002.
2004: Tang W H Wilson; Lincoff A Michael
Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade: the triad revisited.
Circulation 2004;110(24):3618-20.
2004: Stone Gregg W; Bertrand Michel; Colombo Antonio; Dangas George; Farkouh Michael E; Feit Frederick; Lansky Alexandra J; Lincoff A Michael; Mehran Roxana; Moses Jeffrey W; Ohman Magnus; White Harvey D
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
American heart journal 2004;148(5):764-75.
2004: Cohen David J; Lincoff A Michael; Lavelle Tara A; Chen Huei-Ling; Bakhai Ameet; Berezin Ronna H; Jackman Daniel; Sarembock Ian J; Topol Eric J
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Journal of the American College of Cardiology 2004;44(9):1792-800.
2004: Cura Fernando A; Roffi Marco; Pasca Narcis; Wolski Katherine E; Lincoff A Michael; Topol Eric J; Lauer Michael S;
ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy).
The American journal of cardiology 2004;94(7):859-63.
2004: Ellis Stephen G; Bajzer Christopher T; Bhatt Deepak L; Brener Sorin J; Whitlow Patrick L; Lincoff A Michael; Moliterno David J; Raymond Russell E; Tuzcu E Murat; Franco Irving; Dushman-Ellis Sandra; Lander Katherine J; Schneider Jakob P; Topol Eric J
Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2004;63(2):135-40.
2004: Saw Jacqueline; Lincoff A Michael; DeSmet Walter; Betriu Amadeo; Rutsch Wolfgang; Wilcox Robert G; Kleiman Neil S; Wolski Kathy; Topol Eric J;
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Journal of the American College of Cardiology 2004;44(6):1194-9.
2004: Petersen John L; Mahaffey Kenneth W; Becker Richard C; Goodman Shaun G; Kleiman Neal S; Marian A J; Stone Gregg W; Lansky Alexandra J; Lincoff A Michael; Hazen Stanley L; Nessel Christopher C; Toro-Figueroa Luis; Tate Lynn; Reist Craig J; Cohen Marc; Califf Robert M; Ferguson James J;
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
American heart journal 2004;148(2):269-76.
2004: Lincoff A Michael; Kleiman Neal S; Kereiakes Dean J; Feit Frederick; Bittl John A; Jackman J Daniel; Sarembock Ian J; Cohen David J; Spriggs Douglas; Ebrahimi Ramin; Keren Gadi; Carr Jeffrey; Cohen Eric A; Betriu Amadeo; Desmet Walter; Rutsch Wolfgang; Wilcox Robert G; de Feyter Pim J; Vahanian Alec; Topol Eric J;
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
JAMA : the journal of the American Medical Association 2004;292(6):696-703.
2004: Brener Sorin J; Moliterno David J; Lincoff A Michael; Steinhubl Steven R; Wolski Kathy E; Topol Eric J
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Circulation 2004;110(8):994-8.
2004: Rajagopal Vivek; Gurm Hitinder S; Bhatt Deepak L; Lincoff A Michael; Tcheng James E; Kereiakes Dean J; Kleiman Neal S; Jia Gang; Topol Eric J
Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality.
The American journal of cardiology 2004;94(2):190-2.
2004: Gurm Hitinder S; Lincoff A Michael; Kleiman Neil S; Kereiakes Dean J; Tcheng James E; Aronow Herbert D; Askari Arman T; Brennan Danielle M; Topol Eric J
Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions.
The American journal of cardiology 2004;94(1):30-4.
2004: Maroo Anjli; Lincoff A Michael
Bivalirudin in PCI: an overview of the REPLACE-2 trial.
Seminars in thrombosis and hemostasis 2004;30(3):329-36.
2004: Lincoff A Michael; Bittl John A; Kleiman Neal S; Sarembock Ian J; Jackman J Daniel; Mehta Sameer; Tannenbaum Mark A; Niederman Alan L; Bachinsky William B; Tift-Mann J; Parker H Graham; Kereiakes Dean J; Harrington Robert A; Feit Frederick; Maierson Elizabeth S; Chew Derek P; Topol Eric J;
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
The American journal of cardiology 2004;93(9):1092-6.
2004: Dery Jean-Pierre; Braden Gregory A; Lincoff A Michael; Kereiakes Dean J; Browne Kevin; Little Thomas; George Barry S; Sane David C; Cines Douglas B; Effron Mark B; Mascelli Mary Ann; Langrall Mary Ann; Damaraju Lakshmi; Barnathan Elliot S; Tcheng James E;
Final results of the ReoPro readministration registry.
The American journal of cardiology 2004;93(8):979-84.
2004: Alexander J H; Dyke C K; Yang H; Becker R C; Hasselblad V; Zillman L A; Kleiman N S; Hochman J S; Berger P B; Cohen E A; Lincoff A M; Saint-Jacques H; Chetcuti S; Burton J R; Buergler J M; Spence F P; Shimoto Y; Robertson T L; Kunitada S; Bovill E G; Armstrong P W; Harrington R A;
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
Journal of thrombosis and haemostasis : JTH 2004;2(2):234-41.
2004: Roe M T; Mahaffey K W; Kilaru R; Alexander J H; Akkerhuis K M; Simoons M L; Harrington R A; Tardiff B E; Granger C B; Ohman E M; Moliterno D J; Lincoff A M; Armstrong P W; Van de Werf F; Califf R M; Topol E J
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
European heart journal 2004;25(4):313-21.
2004: Lincoff A Michael
Coupling drug and catheter therapy for myocardial infarction.
JAMA : the journal of the American Medical Association 2004;291(8):1000-2.
2004: Gurm Hitinder S; Lincoff A Michael; Lee David; Tang W H Wilson; Jia Gang; Booth Joan E; Califf Robert M; Ohman E M; Van de Werf Frans; Armstrong Paul W; Guetta Victor; Wilcox Robert; Topol Eric J;
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
Journal of the American College of Cardiology 2004;43(4):542-8.
2004: Koster Andreas; Spiess Bruce; Chew Derek P; Krabatsch Thomas; Tambeur Luc; DeAnda Abe; Hetzer Roland; Kuppe Hermann; Smedira Nicholas G; Lincoff A Michael
Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting.
The American journal of cardiology 2004;93(3):356-9.
2004: Exaire J E; Lincoff A M
Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
Journal of thrombosis and haemostasis : JTH 2004;2(1):7-9.
2003: Mukherjee Debabrata; Hsu Amy; Moliterno David J; Lincoff A Michael; Goormastic Marlene; Topol Eric J
Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old.
The American journal of cardiology 2003;92(12):1465-7.
2003: Alexander John H; Harrington Robert A; Bhapkar Manju; Mahaffey Kenneth W; Lincoff A Michael; Ohman E Magnus; Klootwijk Peter; Pahlm Olle; Henden Bo; Deckers Jaap W; Simoons Maarten L; Califf Robert M; Wagner Galen S
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes.
The American journal of medicine 2003;115(8):613-9.
2003: Aronow Herbert D; Novaro Gian M; Lauer Michael S; Brennan Danielle M; Lincoff A Michael; Topol Eric J; Kereiakes Dean J; Nissen Steven E
In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis.
Archives of internal medicine 2003;163(21):2576-82.
2003: Khot Umesh N; Jia Gang; Moliterno David J; Lincoff A Michael; Khot Monica B; Harrington Robert A; Topol Eric J
Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification.
JAMA : the journal of the American Medical Association 2003;290(16):2174-81.
2003: Lincoff A Michael
Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
American heart journal 2003;146(4 Suppl):S23-30.
2003: Chew Derek P; Bhatt Deepak L; Kimball William; Henry Timothy D; Berger Peter; McCullough Peter A; Feit Frederick; Bittl John A; Lincoff A Michael
Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials.
The American journal of cardiology 2003;92(8):919-23.
2003: Gurm H S; Bhatt D L; Lincoff A M; Tcheng J E; Kereiakes D J; Kleiman N S; Jia G; Topol E J
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.
Heart (British Cardiac Society) 2003;89(10):1200-4.
2003: Ellis Keith; Tcheng James E; Sapp Shelly; Topol Eric J; Lincoff A Michael
Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials.
Journal of interventional cardiology 2003;16(4):299-305.
2003: Khot Umesh N; Khot Monica B; Bajzer Christopher T; Sapp Shelly K; Ohman E Magnus; Brener Sorin J; Ellis Stephen G; Lincoff A Michael; Topol Eric J
Prevalence of conventional risk factors in patients with coronary heart disease.
JAMA : the journal of the American Medical Association 2003;290(7):898-904.
2003: Bhatt Deepak L; Chew Derek P; Lincoff A Michael; Simoons Maarten L; Harrington Robert A; Ommen Steve R; Jia Gang; Topol Eric J;
Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes.
The American journal of cardiology 2003;92(2):136-40.
2003: Rao Sunil V; Kaul Padma; Newby L Kristin; Lincoff A Michael; Hochman Judith; Harrington Robert A; Mark Daniel B; Peterson Eric D
Poverty, process of care, and outcome in acute coronary syndromes.
Journal of the American College of Cardiology 2003;41(11):1948-54.
2003: Zhou Zhongmin; Wang Kai; Penn Marc S; Marso Steven P; Lauer Michael A; Forudi Farhad; Zhou Xiaorong; Qu Wu; Lu Yan; Stern David M; Schmidt Ann Marie; Lincoff A Michael; Topol Eric J
Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury.
Circulation 2003;107(17):2238-43.
2003: Wang Kai; Kessler Paul D; Zhou Zhongmin; Penn Marc S; Forudi Farhad; Zhou Xiaorong; Tarakji Khaldoun; Kibbe Melina; Kovesdi Imre; Brough Douglas E; Topol Eric J; Lincoff A Michael
Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;7(5 Pt 1):597-603.
2003: Cho Leslie; Kottke-Marchant Kandice; Lincoff A Michael; Roffi Marco; Reginelli Joel P; Kaldus Theresa; Moliterno David J
Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations.
The American journal of cardiology 2003;91(9):1110-3.
2003: Tcheng James E; Madan Mina; O'Shea J Conor; Cohen Eric A; Buller Christopher E; Lincoff A Michael; Popma Jeffrey J; Teirstein Paul S; Kitt Michael M; Lorenz Todd J; Greenberg Sally; Fost Norman; Califf Robert M
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.
Journal of interventional cardiology 2003;16(2):97-105.
2003: Lincoff A Michael
Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade.
Circulation 2003;107(11):1556-9.
2003: Cho Leslie; Chew Derek P; Moliterno David J; Roffi Marco; Ellis Stephen G; Franco Irving; Bajzer Christopher; Bhatt Deepak L; Dorosti Khosrow; Simpfendorder Conrad; Tuzcu Murat; Yadav Jay S; Brener Sorin; Raymond Russell; Whitlow Patrick; Topol Eric J; Lincoff A Michael
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
The American journal of cardiology 2003;91(6):742-3.
2003: Wang Kai; Zhou Xiaorong; Zhou Zhongmin; Tarakji Khaldoun; Carneiro Marcelo; Penn Marc S; Murray Daniel; Klein Allan; Humphries Robert G; Turner Jonathan; Thomas James D; Topol Eric J; Lincoff A Michael
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(2):357-62.
2003: Lincoff A Michael; Bittl John A; Harrington Robert A; Feit Frederick; Kleiman Neal S; Jackman J Daniel; Sarembock Ian J; Cohen David J; Spriggs Douglas; Ebrahimi Ramin; Keren Gadi; Carr Jeffrey; Cohen Eric A; Betriu Amadeo; Desmet Walter; Kereiakes Dean J; Rutsch Wolfgang; Wilcox Robert G; de Feyter Pim J; Vahanian Alec; Topol Eric J;
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
JAMA : the journal of the American Medical Association 2003;289(7):853-63.
2003: Bhatt Deepak L; Lee Benjamin I; Casterella Peter J; Pulsipher Mark; Rogers Matthew; Cohen Marc; Corrigan Victor E; Ryan Thomas J; Breall Jeffrey A; Moses Jeffrey W; Eaton Gregory M; Sklar Mitchel A; Lincoff A Michael;
Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
Journal of the American College of Cardiology 2003;41(1):20-5.
2002: Blankenship James C; Balog Craig; Sapp Shelly K; Califf Robert M; Lincoff A Michael; Tcheng James E; Topol Eric J
Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2002;57(4):476-83.
2002: Mukherjee Debabrata; Gurm Hitinder; Tang W H Wilson; Roffi Marco; Wolski Kathy; Moliterno David J; Guetta Victor; Ardissinio Diego; Bode Christopher; Steg Gabriel; Lincoff A Michael; Topol Eric J
Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
The American journal of cardiology 2002;90(11):1198-203.
2002: Lincoff A Michael; Califf Robert M; Van de Werf Frans; Willerson James T; White Harvey D; Armstrong Paul W; Guetta Victor; Gibler W Brian; Hochman Judith S; Bode Christoph; Vahanian Alec; Steg P Gabriel; Ardissino Diego; Savonitto Stefano; Bar Frits; Sadowski Zygmunt; Betriu Amadeo; Booth Joan E; Wolski Kathy; Waller Michael; Topol Eric J;
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
JAMA : the journal of the American Medical Association 2002;288(17):2130-5.
2002: Islam M Ashequl; Blankenship James C; Balog Craig; Iliadis Elias A; Lincoff A Michael; Tcheng James E; Califf Robert M; Topol Eric J;
Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
The American journal of cardiology 2002;90(9):916-21.
2002: Zhou Zhongmin; Penn Marc S; Forudi Farhad; Zhou Xiaorong; Tarakji Khaldoun; Topol Eric J; Lincoff A Michael; Wang Kai
Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(10):1598-603.
2002: Kereiakes Dean J; Lincoff A Michael; Anderson Keaven M; Achenbach Robert; Patel Kamlesh; Barnathan Elliot; Califf Robert M; Topol Eric J;
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
The American journal of cardiology 2002;90(6):628-30.
2002: Holmes David R; Savage Michael; LaBlanche J-M; Grip Lars; Serruys P W; Fitzgerald Peter; Fischman David; Goldberg Sheldon; Brinker Jeffrey A; Zeiher A M; Shapiro Leonard M; Willerson James; Davis Barry R; Ferguson James J; Popma Jeffrey; King Spencer B; Lincoff A Michael; Tcheng James E; Chan Robert; Granett Jeffrey R; Poland Marcia
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.
Circulation 2002;106(10):1243-50.
2002: Wang Kai; Zhou Xiaorong; Zhou Zhongmin; Tarakji Khaldoun; Qin Jian Xin; Sitges Marta; Shiota Takahiro; Forudi Farhad; Schaub Robert G; Kumar Anjali; Penn Marc S; Topol Eric J; Lincoff A Michael
Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion.
Thrombosis and haemostasis 2002;88(1):149-54.
2002: Askari Arman T; Lincoff A Michael
GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies to Open Occluded Coronary Arteries.
Cleveland Clinic journal of medicine 2002;69(7):554-60.
2002: Topol Eric J; Lincoff A Michael; Kereiakes Dean J; Kleiman Neal S; Cohen Eric A; Ferguson James J; Tcheng James E; Sapp Shelly; Califf Robert M
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.
The American journal of medicine 2002;113(1):1-6.
2002: Chang W-C; Harrington R A; Simoons M L; Califf R M; Lincoff A M; Armstrong P W;
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.
European heart journal 2002;23(14):1102-11.
2002: Gurm Hitinder S; Brennan Danielle M; Booth Joan; Tcheng James E; Lincoff A Michael; Topol Eric J
Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox).
The American journal of cardiology 2002;90(1):42-5.
2002: Lev Eli I; Marmur Jonathan D; Zdravkovic Milan; Osende Julio I; Robbins Jonathan; Delfin Jenny A; Richard Merwin; Erhardtsen Elisabeth; Thomsen Mikael S; Lincoff A Michael; Badimon Juan J
Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(6):1036-41.
2002: Lincoff A Michael; Kleiman Neal S; Kottke-Marchant Kandace; Maierson Elizabeth S; Maresh Kelly; Wolski Katherine E; Topol Eric J
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
American heart journal 2002;143(5):847-53.
2002: Dyke Christopher K; Becker Richard C; Kleiman Neal S; Hochman Judith S; Bovill Edwin G; Lincoff A Michael; Gerstenblith Gary; Dzavik Vladimir; Gardner Laura H; Hasselblad Vic; Zillman Linda A; Shimoto Yoshimasa; Robertson Thomas L; Kunitada Satoshi; Armstrong Paul W; Harrington Robert A
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Circulation 2002;105(20):2385-91.
2002: Jeremias Allen; Bhatt Deepak L; Chew Derek P; Ziada Khaled M; Albirini Abdulhay; Brener Sorin J; Lincoff A Michael; Topol Eric J; Ellis Stephen G
Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.
The American journal of cardiology 2002;89(10):1209-11.
2002: Ouzan James; Pérault Catherine; Lincoff A Michael; Carré Evelyne; Mertes Michel
The role of spironolactone in the treatment of patients with refractory hypertension.
American journal of hypertension 2002;15(4 Pt 1):333-9.
2002: Yoon Jung Han; Wu Chiung Jen; Homme James; Tuch Ronald J; Wolff Rodney G; Topol Eric J; Lincoff A Michael
Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury model.
Yonsei medical journal 2002;43(2):242-51.
2002: Ellis Stephen G; Lincoff A Michael; Whitlow Patrick L; Raymond Russell E; Franco Irving; Schneider Jakob P; Topol Eric J
Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting.
The American journal of cardiology 2002;89(8):937-40.
2002: Mazur Wojciech; Kaluza Grzegorz L; Sapp Shelly; Balog Craig; Topol Eric J; Mark Daniel B; Ellis Stephen G; Kereiakes Dean J; Lincoff A Michael; Kleiman Neal S
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists.
American heart journal 2002;143(4):594-601.
2002: Zhou Zhongmin; Lauer Michael A; Wang Kai; Forudi Farhad; Zhou Xiaorong; Song Xiao yu; Solowski Nancy; Kapadia Samir R; Nakada Marian T; Topol Eric J; Lincoff A Michael
Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model.
Atherosclerosis 2002;161(1):153-9.
2002: Lincoff A Michael
The GUSTO-V clinical trial.
The Journal of invasive cardiology 2002;14 Suppl A():21A-30A.
2002: Lincoff A Michael
Management of acute coronary syndromes with emphasis on new information for the treatment of ST-segment elevation acute myocardial infarction.
The Journal of invasive cardiology 2002;14 Suppl A():1A-2A.
2002: Akkerhuis K Martijn; Alexander John H; Tardiff Barbara E; Boersma Eric; Harrington Robert A; Lincoff A Michael; Simoons Maarten L
Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?
Circulation 2002;105(5):554-6.
2002: Ronner E; Boersma E; Akkerhuis K M; Harrington R A; Lincoff A M; Deckers J W; Karsch K; Kleiman N S; Vahanian A; Topol E J; Califf R M; Simoons M L
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
European heart journal 2002;23(3):239-46.
2002: Lincoff A Michael
Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarction.
Reviews in cardiovascular medicine 2002;3 Suppl 1():S13-9.
2001: Lincoff A M
Anticoagulant and antiplatelet drugs.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2001;54(4):514-20.
2001: Lauer M A; Houghtaling P L; Peterson J G; Granger C B; Bhatt D L; Sapp S K; Simoons M L; Harrington R A; Topol E J; Lincoff A M;
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Circulation 2001;104(23):2772-7.
2001: Ellis S G; Brener S J; Lincoff A M; Moliterno D J; Whitlow P L; Schneider J P; Topol E J
beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise.
Circulation 2001;104(22):2685-8.
2001: Tcheng J E; Talley J D; O'Shea J C; Gilchrist I C; Kleiman N S; Grines C L; Davidson C J; Lincoff A M; Califf R M; Jennings L K; Kitt M M; Lorenz T J
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
The American journal of cardiology 2001;88(10):1097-102.
2001: Tcheng J E; Kereiakes D J; Lincoff A M; George B S; Kleiman N S; Sane D C; Cines D B; Jordan R E; Mascelli M A; Langrall M A; Damaraju L; Schantz A; Effron M B; Braden G A
Abciximab readministration: results of the ReoPro Readministration Registry.
Circulation 2001;104(8):870-5.
2001: Park S H; Marso S P; Zhou Z; Foroudi F; Topol E J; Lincoff A M
Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus.
Circulation 2001;104(7):815-9.
2001: Wang K; Zhou Z; Zhou X; Tarakji K; Topol E J; Lincoff A M
Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model.
Journal of the American College of Cardiology 2001;38(2):577-82.
2001: Tardiff B E; Jennings L K; Harrington R A; Gretler D; Potthoff R F; Vorchheimer D A; Eisenberg P R; Lincoff A M; Labinaz M; Joseph D M; McDougal M F; Kleiman N S;
Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
Circulation 2001;104(4):399-405.
2001: Lincoff A M; Kereiakes D J; Mascelli M A; Deckelbaum L I; Barnathan E S; Patel K K; Frederick B; Nakada M T; Topol E J
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.
Circulation 2001;104(2):163-7.
2001: Akkerhuis K M; Deckers J W; Lincoff A M; Tcheng J E; Boersma E; Anderson K; Balog C; Califf R M; Topol E J; Simoons M L
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.
JAMA : the journal of the American Medical Association 2001;286(1):78-82.
2001: Lincoff A M
Combination therapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa receptor inhibitors: SPEEDing into GUSTO V.
The Journal of invasive cardiology 2001;13 Suppl A():16A-18A.
2001: Aronow H D; Topol E J; Roe M T; Houghtaling P L; Wolski K E; Lincoff A M; Harrington R A; Califf R M; Ohman E M; Kleiman N S; Keltai M; Wilcox R G; Vahanian A; Armstrong P W; Lauer M S
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.
Lancet 2001;357(9262):1063-8.
2001: Peterson J G; Topol E J; Roe M T; Sapp S K; Lincoff A M; Deckers J W; Blackstone E H; Harrington R A; Califf R M; Lauer M S
Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
The American journal of cardiology 2001;87(5):532-6.
2001: Greenbaum A B; Harrington R A; Hudson M P; MacAulay C M; Wilcox R G; Simoons M L; Berdan L G; Guerci A; Cokkinos D V; Kitt M M; Lincoff A M; Topol E J; Califf R M; Ohman E M
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
Journal of the American College of Cardiology 2001;37(2):492-8.
2001: Chew D P; Bhatt D L; Lincoff A M; Moliterno D J; Brener S J; Wolski K E; Topol E J
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
Circulation 2001;103(7):961-6.
2000: Lincoff A M; Mark D B; Tcheng J E; Califf R M; Bala M V; Anderson K M; Davidson-Ray L; Knight J D; Cabot C F; Topol E J
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Circulation 2000;102(24):2923-9.
2000: Lincoff A M
GUSTO IV: expanding therapeutic options in acute coronary syndromes.
American heart journal 2000;140(6 Suppl):S103-14.
2000: Herrmann H C; Moliterno D J; Ohman E M; Stebbins A L; Bode C; Betriu A; Forycki F; Miklin J S; Bachinsky W B; Lincoff A M; Califf R M; Topol E J
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.
Journal of the American College of Cardiology 2000;36(5):1489-96.
2000: Peterson J G; Topol E J; Sapp S K; Young J B; Lincoff A M; Lauer M S
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
The American journal of medicine 2000;109(5):371-7.
2000: Roe M T; Harrington R A; Prosper D M; Pieper K S; Bhatt D L; Lincoff A M; Simoons M L; Akkerhuis M; Ohman E M; Kitt M M; Vahanian A; Ruzyllo W; Karsch K; Califf R M; Topol E J
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
Circulation 2000;102(10):1101-6.
2000: Lincoff A M; Harrington R A; Califf R M; Hochman J S; Guerci A D; Ohman E M; Pepine C J; Kopecky S L; Kleiman N S; Pacchiana C M; Berdan L G; Kitt M M; Simoons M L; Topol E J
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Circulation 2000;102(10):1093-100.
2000: Lincoff A M; LeNarz L A; Despotis G J; Smith P K; Booth J E; Raymond R E; Sapp S K; Cabot C F; Tcheng J E; Califf R M; Effron M B; Topol E J
Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.
The Annals of thoracic surgery 2000;70(2):516-26.
2000: Cho L; Topol E J; Balog C; Foody J M; Booth J E; Cabot C; Kleiman N S; Tcheng J E; Califf R; Lincoff A M
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Journal of the American College of Cardiology 2000;36(2):381-6.
2000: Cura F A; Bhatt D L; Lincoff A M; Kapadia S R; L'Allier P L; Ziada K M; Wolski K E; Moliterno D J; Brener S J; Ellis S G; Topol E J
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
Circulation 2000;102(1):28-34.
2000: Kereiakes D J; Berkowitz S D; Lincoff A M; Tcheng J E; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf R M; Topol E J
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
American heart journal 2000;140(1):74-80.
2000: Boersma E; Pieper K S; Steyerberg E W; Wilcox R G; Chang W C; Lee K L; Akkerhuis K M; Harrington R A; Deckers J W; Armstrong P W; Lincoff A M; Califf R M; Topol E J; Simoons M L
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
Circulation 2000;101(22):2557-67.
2000: Bhatt D L; Lincoff A M; Califf R M; Simoons M L; Tcheng J E; Brener S J; Wolski K E; Topol E J
The benefit of abciximab in percutaneous coronary revascularization is not device-specific.
The American journal of cardiology 2000;85(9):1060-4.
2000: Campbell K R; Ohman E M; Cantor W; Lincoff A M
The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
The American journal of cardiology 2000;85(8A):32C-8C.
2000: Lincoff A M; Califf R M; Topol E J
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Journal of the American College of Cardiology 2000;35(5):1103-15.
2000: Bhatt D L; Marso S P; Lincoff A M; Wolski K E; Ellis S G; Topol E J
Abciximab reduces mortality in diabetics following percutaneous coronary intervention.
Journal of the American College of Cardiology 2000;35(4):922-8.
2000: Akkerhuis K M; Deckers J W; Boersma E; Harrington R A; Stepinska J; Mahaffey K W; Wilcox R G; Lincoff A M; Keltai M; Topol E J; Califf R M; Simoons M L
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
European heart journal 2000;21(5):371-81.
2000: Thel M C; Califf R M; Tardiff B E; Gardner L H; Sigmon K N; Lincoff A M; Topol E J; Kitt M M; Blankenship J C; Tcheng J E
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
The American journal of cardiology 2000;85(4):427-34.
2000: Kleiman N S; Lincoff A M; Flaker G C; Pieper K S; Wilcox R G; Berdan L G; Lorenz T J; Cokkinos D V; Simoons M L; Boersma E; Topol E J; Califf R M; Harrington R A
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.
Circulation 2000;101(7):751-7.
2000: Mark D B; Harrington R A; Lincoff A M; Califf R M; Nelson C L; Tsiatis A A; Buell H; Mahaffey K W; Davidson-Ray L; Topol E J
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.
Circulation 2000;101(4):366-71.
2000: Lincoff A M
Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial.
American heart journal 2000;139(2 Pt 2):S46-52.
2000: Holmes D; Fitzgerald P; Goldberg S; LaBlanche J m; Lincoff A M; Savage M; Serruys P W; Willerson J; Granett J R; Chan R; Shusterman N H; Poland M
The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial.
American heart journal 2000;139(1 Pt 1):23-31.
1999: Topol E J; Mark D B; Lincoff A M; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot C F; Anderson K M; Califf R M
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Lancet 1999;354(9195):2019-24.
1999: Robbins M A; Marso S P; Wolski K; Peterson J; Lincoff A M; Brener S
Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT]).]
The American journal of cardiology 1999;84(11):1350-3, A8.
1999: Marso S P; Lincoff A M; Ellis S G; Bhatt D L; Tanguay J F; Kleiman N S; Hammoud T; Booth J E; Sapp S K; Topol E J
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
Circulation 1999;100(25):2477-84.
1999: Gilchrist I C; Gardner L H; Muhlestein J B; Arnold A M; Lincoff A M; Califf R M; Tcheng J E; Topol E J
Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience.
American heart journal 1999;138(5 Pt 1):976-82.
1999: Lincoff A M; Califf R M; Moliterno D J; Ellis S G; Ducas J; Kramer J H; Kleiman N S; Cohen E A; Booth J E; Sapp S K; Cabot C F; Topol E J
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
The New England journal of medicine 1999;341(5):319-27.
1999: McClure M W; Berkowitz S D; Sparapani R; Tuttle R; Kleiman N S; Berdan L G; Lincoff A M; Deckers J; Diaz R; Karsch K R; Gretler D; Kitt M; Simoons M; Topol E J; Califf R M; Harrington R A
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
Circulation 1999;99(22):2892-900.
1999: Mahaffey K W; Harrington R A; Simoons M L; Granger C B; Graffagnino C; Alberts M J; Laskowitz D T; Miller J M; Sloan M A; Berdan L G; MacAulay C M; Lincoff A M; Deckers J; Topol E J; Califf R M
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Circulation 1999;99(18):2371-7.
1999: Alexander J H; Harrington R A; Tuttle R H; Berdan L G; Lincoff A M; Deckers J W; Simoons M L; Guerci A; Hochman J S; Wilcox R G; Kitt M M; Eisenberg P R; Califf R M; Topol E J; Karsh K; Ruzyllo W; Stepinska J; Widimsky P; Boland J B; Armstrong P W
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
The American journal of cardiology 1999;83(8):1147-51.
1999: Lincoff A M; Tcheng J E; Califf R M; Kereiakes D J; Kelly T A; Timmis G C; Kleiman N S; Booth J E; Balog C; Cabot C F; Anderson K M; Weisman H F; Topol E J
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Circulation 1999;99(15):1951-8.
1999: Ellis S G; Miller D; Keys T F; Brown K; Ellert R; Howell G; Lincoff A M; Topol E J
Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and results.
Journal of the American College of Cardiology 1999;33(5):1278-85.
1999: Smith J W; Steinhubl S R; Lincoff A M; Coleman J C; Lee T T; Hillman R S; Coller B S
Rapid platelet-function assay: an automated and quantitative cartridge-based method.
Circulation 1999;99(5):620-5.
1999: Thel M C; Califf R M; Tcheng J E; Sigmon K N; Lincoff A M; Topol E J; Ellis S G
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators.
American heart journal 1999;137(2):264-73.
1999: Harrington R A; Califf R M; Holmes D R; Pieper K S; Lincoff A M; Berdan L G; Thompson T D; Topol E J
Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators.
American heart journal 1999;137(2):227-33.
1999: Tardiff B E; Califf R M; Tcheng J E; Lincoff A M; Sigmon K N; Harrington R A; Mahaffey K W; Ohman E M; Teirstein P S; Blankenship J C; Kitt M M; Topol E J
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
Journal of the American College of Cardiology 1999;33(1):88-96.
1998: Kong D F; Califf R M; Miller D P; Moliterno D J; White H D; Harrington R A; Tcheng J E; Lincoff A M; Hasselblad V; Topol E J
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.
Circulation 1998;98(25):2829-35.
1998: Ellis S G; Lincoff A M; Miller D; Tcheng J E; Kleiman N S; Kereiakes D; Califf R; Topol E J
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.
Journal of the American College of Cardiology 1998;32(6):1619-23.
1998: Bhatt D L; Lincoff A M; Kereiakes D J; Tcheng J E; Simoons M L; van der Wieken L R; Godfrey N; Califf R M; Topol E J
Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.
The American journal of cardiology 1998;82(9):1105-6, A6.
1998: Steinhubl S R; Lauer M S; Mukherjee D P; Moliterno D J; Lincoff A M; Ellis S G; Topol E J
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.
Journal of the American College of Cardiology 1998;32(5):1366-70.
1998: Lincoff A M
Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
The American journal of cardiology 1998;82(8B):36P-42P.
1998: Kleiman N S; Lincoff A M; Ohman E M; Harrington R A
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings.
American heart journal 1998;136(4 Pt 2 Su):S32-42.
1998: Ghaffari S; Kereiakes D J; Lincoff A M; Kelly T A; Timmis G C; Kleiman N S; Ferguson J J; Miller D P; Califf R A; Topol E J
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
The American journal of cardiology 1998;82(1):7-12.
1998: Mandak J S; Blankenship J C; Gardner L H; Berkowitz S D; Aguirre F V; Sigmon K N; Timmis G C; Gilchrist I C; McIvor M; Resar J; Weiner B H; George B S; Talley J D; Lincoff A M; Tcheng J E; Califf R M; Topol E J
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Journal of the American College of Cardiology 1998;31(7):1518-24.
1998: Kleiman N S; Lincoff A M; Kereiakes D J; Miller D P; Aguirre F V; Anderson K M; Weisman H F; Califf R M; Topol E J
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Circulation 1998;97(19):1912-20.
1998: Kereiakes D J; Lincoff A M; Miller D P; Tcheng J E; Cabot C F; Anderson K M; Weisman H F; Califf R M; Topol E J
Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.
Circulation 1998;97(9):857-64.
1997: Steinhubl S R; Lincoff A M
Antithrombotic therapy with intracoronary stenting.
Heart (British Cardiac Society) 1997;78 Suppl 2():21-3.
1997: Lincoff A M; Califf R M; Anderson K M; Weisman H F; Aguirre F V; Kleiman N S; Harrington R A; Topol E J
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Journal of the American College of Cardiology 1997;30(1):149-56.
1997: Lincoff A M; Furst J G; Ellis S G; Tuch R J; Topol E J
Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model.
Journal of the American College of Cardiology 1997;29(4):808-16.
1997: Gottsauner-Wolf M; Jang Y; Lincoff A M; Cohen J L; Labhasetwar V; Poptic E J; Forudi F; Guzman L A; DiCorleto P E; Levy R J; Topol E J; Ellis S G
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model.
American heart journal 1997;133(3):329-34.
1997: Lincoff A M; Tcheng J E; Califf R M; Bass T; Popma J J; Teirstein P S; Kleiman N S; Hattel L J; Anderson H V; Ferguson J J; Cabot C F; Anderson K M; Berdan L G; Musco M H; Weisman H F; Topol E J
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
The American journal of cardiology 1997;79(3):286-91.
1996: Schulman S P; Goldschmidt-Clermont P J; Topol E J; Califf R M; Navetta F I; Willerson J T; Chandra N C; Guerci A D; Ferguson J J; Harrington R A; Lincoff A M; Yakubov S J; Bray P F; Bahr R D; Wolfe C L; Yock P G; Anderson H V; Nygaard T W; Mason S J; Effron M B; Fatterpacker A; Raskin S; Smith J; Brashears L; Gottdiener P; du Mee C; Kitt M M; Gerstenblith G
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Circulation 1996;94(9):2083-9.
1996: Guzman L A; Labhasetwar V; Song C; Jang Y; Lincoff A M; Levy R; Topol E J
Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty.
Circulation 1996;94(6):1441-8.
1996: Gottsauner-Wolf M; Moliterno D J; Lincoff A M; Topol E J
Restenosis--an open file.
Clinical cardiology 1996;19(5):347-56.
1995: Harrington R A; Kleiman N S; Kottke-Marchant K; Lincoff A M; Tcheng J E; Sigmon K N; Joseph D; Rios G; Trainor K; Rose D
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
The American journal of cardiology 1995;76(17):1222-7.
1995: Ohman E M; Harrington R A; Lincoff A M; Kitt M M; Kleiman N S; Tcheng J E
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor.
European heart journal 1995;16 Suppl L():50-5.
1995: Califf R M; Lincoff A M; Tcheng J E; Topol E J
An overview of the results of the EPIC trial.
European heart journal 1995;16 Suppl L():43-9.
1995: Jang Y; Guzman L A; Lincoff A M; Gottsauner-Wolf M; Forudi F; Hart C E; Courtman D W; Ezban M; Ellis S G; Topol E J
Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model.
Circulation 1995;92(10):3041-50.
1995: Harrington R A; Lincoff A M; Califf R M; Holmes D R; Berdan L G; O'Hanesian M A; Keeler G P; Garratt K N; Ohman E M; Mark D B
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT).
Journal of the American College of Cardiology 1995;25(7):1693-9.
1995: Lincoff A M; Topol E J; Califf R M; Sigmon K N; Lee K L; Ohman E M; Rosenschein U; Ellis S G
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
The American journal of cardiology 1995;75(14):871-6.
1995: Ellis S G; Cowley M J; Whitlow P L; Vandormael M; Lincoff A M; DiSciascio G; Dean L S; Topol E J
Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS) Group.
Journal of the American College of Cardiology 1995;25(5):1137-42.
1994: Jang Y; Lincoff A M; Plow E F; Topol E J
Cell adhesion molecules in coronary artery disease.
Journal of the American College of Cardiology 1994;24(7):1591-601.
1994: Lincoff A M; Topol E J; Ellis S G
Local drug delivery for the prevention of restenosis. Fact, fancy, and future.
Circulation 1994;90(4):2070-84.
1994: Lincoff A M
Patients at high risk for ischemic complications.
The Journal of invasive cardiology 1994;6 Suppl A():13A-18A; discussion 50A-51A.
1993: Lincoff A M; Califf R M; Ellis S G; Sigmon K N; Lee K L; Leimberger J D; Topol E J
Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Journal of the American College of Cardiology 1993;22(7):1780-7.
1993: Lincoff A M; Topol E J
Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
Circulation 1993;88(3):1361-74.
1993: Lincoff A M; Topol E J; Chapekis A T; George B S; Candela R J; Muller D W; Zimmerman C A; Ellis S G
Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control study.
Journal of the American College of Cardiology 1993;21(4):866-75.

Sign-in to see more